Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA test results from 450 prostate cancer specimens. The findings suggest that ...

BRCA1 and BRCA2 gene mutations increase the risk of hereditary breast cancer. Here's what you should know about the causes, genetic testing options, and prevention strategies to manage your cancer ...

Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A ...

Carriers of the BRCA1 cancer gene had a significantly increased risk of breast cancer if they used hormonal contraception (HC), pooled cohort data showed. Breast cancer risk increased by 29% in BRCA1 ...

A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 mutation status informing individualized risk stratification and counseling.

Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...

Harmful variants in the BRCA1 gene greatly increase a person's lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...

An estimated 170,000 Australians were diagnosed with cancer in 2025. Many people know the causes of cancer are partly genetic. But how do your genes, which contribute so much of what makes you you, ...